Robert Lawatscheck

1.0k total citations
31 papers, 519 citations indexed

About

Robert Lawatscheck is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Epidemiology. According to data from OpenAlex, Robert Lawatscheck has authored 31 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Endocrinology, Diabetes and Metabolism, 11 papers in Cardiology and Cardiovascular Medicine and 7 papers in Epidemiology. Recurrent topics in Robert Lawatscheck's work include Hormonal Regulation and Hypertension (16 papers), Blood Pressure and Hypertension Studies (8 papers) and Diabetes Treatment and Management (8 papers). Robert Lawatscheck is often cited by papers focused on Hormonal Regulation and Hypertension (16 papers), Blood Pressure and Hypertension Studies (8 papers) and Diabetes Treatment and Management (8 papers). Robert Lawatscheck collaborates with scholars based in Germany, United States and Denmark. Robert Lawatscheck's co-authors include Peter Rossing, Gerasimos Filippatos, George L. Bakris, Luís M. Ruilope, Stefan D. Anker, Bertram Pitt, Amer Joseph, Peter Kolkhof, Rajiv Agarwal and Katherine R. Tuttle and has published in prestigious journals such as New England Journal of Medicine, Diabetes Care and International Journal of Molecular Sciences.

In The Last Decade

Robert Lawatscheck

27 papers receiving 508 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Lawatscheck Germany	14	258	149	146	79	72	31	519
Ritu Karoli India	14	134 0.5×	74 0.5×	22 0.2×	34 0.4×	94 1.3×	55	589
Michael Jaker United States	8	125 0.5×	58 0.4×	35 0.2×	20 0.3×	53 0.7×	16	305
Sanjay Sarin India	15	38 0.1×	196 1.3×	44 0.3×	125 1.6×	134 1.9×	39	662
Wu–Chang Yang Taiwan	11	29 0.1×	52 0.3×	57 0.4×	66 0.8×	58 0.8×	26	461
Jailan Osman United States	6	75 0.3×	18 0.1×	36 0.2×	48 0.6×	182 2.5×	8	394
Kyle Matschke United States	15	95 0.4×	29 0.2×	40 0.3×	116 1.5×	57 0.8×	60	545
Delma Nieves United States	7	102 0.4×	64 0.4×	28 0.2×	33 0.4×	217 3.0×	17	410
María Heredia‐Rodríguez Spain	16	21 0.1×	89 0.6×	82 0.6×	93 1.2×	309 4.3×	37	641
Yukihisa Miyazawa Japan	12	63 0.2×	33 0.2×	30 0.2×	63 0.8×	107 1.5×	37	488
Ana-Maria Sîngeap Romania	15	82 0.3×	30 0.2×	90 0.6×	87 1.1×	469 6.5×	83	916

Countries citing papers authored by Robert Lawatscheck

Since Specialization

Citations

This map shows the geographic impact of Robert Lawatscheck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Lawatscheck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Lawatscheck more than expected).

Fields of papers citing papers by Robert Lawatscheck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Lawatscheck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Lawatscheck. The network helps show where Robert Lawatscheck may publish in the future.

Co-authorship network of co-authors of Robert Lawatscheck

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Lawatscheck. A scholar is included among the top collaborators of Robert Lawatscheck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Lawatscheck. Robert Lawatscheck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mentz, Robert J., Stefan D. Anker, Bertram Pitt, et al.. (2025). Efficacy and Safety of Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes By Diuretic Use: A FIDELITY Analysis. European Journal of Heart Failure. 27(5). 764–774.

Heerspink, Hiddo J.L., Rajiv Agarwal, Antonio J. Amor, et al.. (2025). Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations. Nephrology Dialysis Transplantation. 41(3). 556–565. 1 indexed citations

Pitt, Bertram, Rajiv Agarwal, Stefan D. Anker, et al.. (2024). Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis. European Heart Journal - Cardiovascular Pharmacotherapy. 11(1). 10–19. 1 indexed citations

Ebert, Thomas, Stefan D. Anker, Luís M. Ruilope, et al.. (2023). Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance. Diabetes Care. 47(3). 362–370. 19 indexed citations

Rossing, Peter, Stefan D. Anker, Gerasimos Filippatos, et al.. (2023). The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study. Diabetes Obesity and Metabolism. 25(10). 2989–2998. 8 indexed citations

Heerspink, Hiddo J.L., Andreas L. Birkenfeld, David Z.I. Cherney, et al.. (2023). Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Research and Clinical Practice. 204. 110908–110908. 27 indexed citations

Rosas, Sylvia E., Luís M. Ruilope, Stefan D. Anker, et al.. (2023). Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis. Kidney Medicine. 5(10). 100704–100704. 1 indexed citations

Koya, Daisuke, Stefan D. Anker, Luís M. Ruilope, et al.. (2023). Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis. American Journal of Nephrology. 54(9-10). 370–378. 10 indexed citations

Agarwal, Rajiv, Bertram Pitt, Peter Rossing, et al.. (2023). Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone. JAMA Cardiology. 8(8). 732–732. 21 indexed citations

10.

Flack, John M., Rajiv Agarwal, Stefan D. Anker, et al.. (2023). Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials. Kidney Medicine. 5(12). 100730–100730.

11.

Agarwal, Rajiv, Bertram Pitt, Biff F. Palmer, et al.. (2022). A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clinical Kidney Journal. 16(2). 293–302. 57 indexed citations

12.

Bakris, George L., Luís M. Ruilope, Stefan D. Anker, et al.. (2022). A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney International. 103(1). 196–206. 46 indexed citations

13.

Filippatos, Gerasimos, Stefan D. Anker, Bertram Pitt, et al.. (2022). Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes. JACC Heart Failure. 10(11). 860–870. 43 indexed citations

14.

Agarwal, Rajiv, Stefan D. Anker, Bertram Pitt, et al.. (2021). Association of Urine Albumin-to-Creatinine Ratio and Its Early Change with Cardiorenal Outcomes in FIDELIO-DKD: A Mediation Analysis. Journal of the American Society of Nephrology. 32(10S). B5–B5.

15.

Fox, Keith A.A., Sonia S. Anand, Victor Aboyans, et al.. (2020). Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both. American Heart Journal. 222. 166–173. 13 indexed citations

16.

Spies, Claudia, et al.. (2019). Does Telemedical Support of First Responders Improve Guideline Adherence in an Offshore Emergency Scenario? A Simulator-Based Prospective Study. BMJ Open. 9(8). e027563–e027563. 4 indexed citations

17.

Lawatscheck, Robert, et al.. (2012). ALARM: A Modular IT Solution to Support and Evaluate Mass Casualty Incident (MCI) Management. ISCRAM. 2 indexed citations

18.

Dorn, David C., Robert Lawatscheck, Aurelija Žvirblienė, et al.. (2008). Cellular and Humoral Immunogenicity of Hamster Polyomavirus-Derived Virus-Like Particles Harboring a Mucin 1 Cytotoxic T-Cell Epitope. Viral Immunology. 21(1). 12–26. 15 indexed citations

19.

Lawatscheck, Robert, Jörg A. Schenk, Burkhard Micheel, et al.. (2007). Chimeric Polyomavirus-Derived Virus-Like Particles: The Immunogenicity of an Inserted Peptide Applied without Adjuvant to Mice Depends on Its Insertion Site and Its Flanking Linker Sequence. Viral Immunology. 20(3). 453–460. 12 indexed citations

20.

Gedvilaitė, Alma, David C. Dorn, Kęstutis Sasnauskas, et al.. (2006). Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells. Virology. 354(2). 252–260. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact